Victoza

What is Victoza?

Victoza is a prescription injectable medication containing liraglutide, a once-daily GLP-1 receptor agonist manufactured by Novo Nordisk. The FDA approved Victoza on January 25, 2010, under new drug application number 022341 for adults with type 2 diabetes, making it one of the oldest GLP-1 agonists still in active clinical use in the United States. The label was expanded in August 2017 to include reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial. In June 2019, the FDA approved Victoza for pediatric type 2 diabetes in patients aged 10 and older. Victoza is administered as a once-daily subcutaneous injection at doses of 1.2 mg or 1.8 mg and contains the same active ingredient as Saxenda, marketed at a lower dose for diabetes rather than weight management. While Victoza has been largely superseded by weekly GLP-1 agents (Ozempic, Mounjaro) for most new prescriptions, it remains a viable option for patients who prefer daily dosing, have a long history of tolerating liraglutide, or have insurance that preferentially covers it.

How Victoza works

Victoza works by mimicking GLP-1, the natural incretin hormone released by the small intestine after meals. Liraglutide binds the GLP-1 receptor and produces four coordinated effects: it stimulates glucose-dependent insulin release (only when blood sugar is elevated, which makes hypoglycemia with Victoza alone unlikely), suppresses glucagon release from pancreatic alpha cells, slows gastric emptying so post-meal glucose rises more gradually, and reduces appetite through action on hypothalamic satiety centers. Because liraglutide has a half-life of approximately 13 hours, it requires daily dosing to maintain steady drug exposure — compared with the weekly dosing possible for semaglutide and tirzepatide, both of which are engineered for longer durations. Steady-state plasma concentrations are reached within three to four days of consistent daily dosing, and the titration schedule is therefore weekly rather than monthly. The 1.2 mg and 1.8 mg Victoza doses are calibrated for glycemic control in type 2 diabetes, while the higher 3 mg Saxenda dose targets appetite suppression for weight management.

Who Victoza is for

Victoza is FDA-approved for three distinct patient populations:

• Adults with type 2 diabetes — as an adjunct to diet and exercise to improve glycemic control.
• Adults with type 2 diabetes and established cardiovascular disease — to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). This indication is backed by the LEADER trial, which showed a 13 percent reduction in the primary composite endpoint over 3.8 years of follow-up.
• Pediatric patients aged 10 and older with type 2 diabetes — Victoza was the first GLP-1 agonist approved for pediatric type 2 diabetes, based on the ELLIPSE trial.

Your prescriber will evaluate current A1C and glycemic trajectory, body mass index, kidney function, cardiovascular risk, history of pancreatitis or gallbladder disease, family history of medullary thyroid carcinoma or MEN 2, and insurance coverage. Victoza is not FDA-approved for type 1 diabetes, weight management on its own (Saxenda is the liraglutide product for weight loss), use during pregnancy or breastfeeding, or patients under age 10.

How to take Victoza

Victoza is administered as a subcutaneous injection once daily, at any time of day, with or without food. Most patients pick a specific daily time and stick with it for consistency — many find morning or evening before bed works best. The injection is given into the abdomen, thigh, or upper arm, rotating sites between doses. The Victoza pen is reusable with disposable needles; use a new needle each time and never share a pen between individuals.

The titration schedule is 0.6 mg daily for one week (starter dose, not therapeutic), then 1.2 mg daily. This is the first effective maintenance dose for glycemic control. If additional A1C reduction is needed, the dose can be increased to 1.8 mg daily after one week at 1.2 mg. The maximum approved dose is 1.8 mg daily. Your prescriber may keep you at 1.2 mg if glycemic control is adequate at that level, or hold titration if side effects are bothersome. Pediatric patients may be limited to 1.8 mg even when adult guidance would allow advancement.

If you miss a dose and it is within 12 hours of your usual injection time, take it as soon as you remember. If more than 12 hours have passed, skip the missed dose and resume your regular schedule the next day. Do not take two doses to make up for a missed one. If you miss three or more consecutive days, contact your prescriber; you may need to restart titration at 0.6 mg to re-establish tolerance. Store unopened pens in the refrigerator between 36°F and 46°F (2-8°C). After first use, pens can be stored either refrigerated or at room temperature (up to 86°F / 30°C) for up to 30 days.

Side effects of Victoza

Victoza's side-effect profile is similar to other GLP-1 receptor agonists, with gastrointestinal effects most prominent during the weekly titration and early maintenance period. All frequencies below come from the Victoza clinical trial program pooled data in the FDA prescribing information.

Common side effects (worst during titration, typically improving over 2-4 weeks):

• Nausea — reported in approximately 28 percent of patients, most pronounced during the first two weeks
• Diarrhea — 17 percent
• Headache — 14 percent
• Vomiting — 11 percent
• Decreased appetite — welcome in most patients with concurrent overweight
• Dyspepsia (indigestion), constipation — each in the 7 to 10 percent range
• Injection site reactions — 2 percent, typically minor
• Upper respiratory tract infection — 10 percent, slightly elevated above background

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 1 percent) — severe, persistent upper abdominal pain radiating to the back
• Gallbladder disease (cholelithiasis, cholecystitis) — can occur during treatment
• Acute kidney injury — usually secondary to dehydration from persistent GI symptoms
• Hypoglycemia — uncommon with Victoza alone but rises sharply when combined with insulin or sulfonylureas
• Diabetic retinopathy complications — rapid improvement in glycemia may temporarily worsen pre-existing retinopathy
• Serious allergic reactions — anaphylaxis and angioedema have been reported post-marketing

Management strategies — stay an extra week at a given dose step before advancing if side effects are bothersome, eat smaller meals more frequently, avoid high-fat or very spicy foods during titration, stay well hydrated, and limit alcohol. Contact your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, or any rapid symptom change.

Who should not take Victoza

Victoza is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to liraglutide or any component of the formulation
• Pregnancy — liraglutide crosses the placenta in animal studies and can affect fetal development

Boxed warning: Liraglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma, in rodent studies. It is unknown whether liraglutide causes such tumors in humans. Patients should be counseled to report any persistent neck mass, dysphagia, dyspnea, or hoarseness.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastroparesis or other significant GI motility disorder, significant kidney impairment, pre-existing diabetic retinopathy, or breastfeeding. Because Victoza slows gastric emptying, the absorption of orally administered medications may be delayed — review oral contraceptives, thyroid hormone, warfarin, and time-critical cardiovascular drugs with your pharmacist. Concurrent use with other GLP-1 receptor agonists (Saxenda — which contains the same active ingredient at a higher dose — as well as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Byetta, Bydureon, Foundayo) is not recommended and produces no additional benefit.

What to expect on Victoza

Victoza's therapeutic response appears gradually over the first two to three months and then sustains with consistent daily dosing.

Week 1 (0.6 mg starter dose). This is a dose-adjustment phase. Blood sugar may improve marginally but the dose is not therapeutic. Most patients feel some nausea, particularly on days 2-4, which typically resolves within the week. Appetite suppression may become noticeable by end of week.

Week 2 onward (1.2 mg maintenance). A1C starts to improve measurably. Fasting glucose typically drops within the first two weeks. Post-meal glucose excursions shrink as gastric emptying slows. Weight loss is modest — averaging 2 to 3 kg by month 3 — because the 1.2 mg dose is calibrated for glycemic rather than weight control.

Month 2 to month 6 (1.2 mg or 1.8 mg). Mean A1C reduction at 26 weeks on 1.8 mg in pooled trials was approximately 1.1 percentage points from baseline. Average weight loss was 2 to 3 kg. GI side effects typically settle as the body adapts to consistent daily dosing.

Beyond 6 months and long-term. Patients who continue Victoza generally sustain their glycemic improvement. The LEADER cardiovascular outcomes trial followed patients for a median of 3.8 years and showed a 13 percent reduction in major adverse cardiovascular events, with benefit emerging over the first two years of treatment. Your prescriber will schedule follow-up every three to six months to monitor A1C, weight, kidney function, and cardiovascular risk markers. Discontinuation typically reverses the glycemic and modest weight improvements within three to six months as the medication clears and appetite returns to baseline.

Victoza cost and coverage

The list price of Victoza is approximately $950 per two-pen pack (one month of therapy at 1.8 mg daily) before insurance, based on the Novo Nordisk wholesale acquisition cost. Liraglutide patents have begun to erode — the first FDA-approved generic liraglutide (Liraglutide GLP-1) launched in 2024 in the United States and is priced substantially below branded Victoza.

What you actually pay depends heavily on coverage:

• Commercial insurance (Type 2 diabetes): Most major plans cover Victoza for patients with a confirmed type 2 diabetes diagnosis, typically with prior authorization. Copays commonly range from $25 to $100 per month on preferred tiers.
• Medicare Part D: Covers Victoza for type 2 diabetes. The Inflation Reduction Act caps total annual out-of-pocket prescription spending at $2,000 for Part D beneficiaries starting in 2025.
• Medicaid: Generally covers Victoza for type 2 diabetes, though prior-authorization rules vary by state.
• Generic liraglutide: Now available in pharmacies at lower cost than branded Victoza; ask your pharmacist about substitution. Generic versions have identical clinical effect when properly formulated.
• Manufacturer savings: The Novo Nordisk Victoza Savings Card can reduce eligible commercially-insured patients' copay to as low as $25 per month; not available to Medicare or Medicaid beneficiaries.
• Patient assistance: Uninsured patients meeting income criteria may qualify for the Novo Nordisk Patient Assistance Program.

Check your specific plan, the current manufacturer savings program, and the availability of generic liraglutide at your pharmacy before filling — pricing for this class of drug is evolving as patents expire.